Names of anticancer molécules under consideration by the United States Adopted Names (USAN) Council

USAN Council's statement on the use of USAN as domain names:

A name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names Web site, shall be the effective equivalent of an intellectual property right on the part of the relevant entities.

The following list of names for the drugs described are "under consideration" by the USAN Council:

July - September, 2011

birinacip

clazakizumab

crisantaspase (acute lymphoblastic leukemia)

enzandrant

gemcitabine elaidate (pancreatic cancer)

momelotinib (myeloproliferative disorders)

nivolumab

ocaratuzumab (B-cell non-Hodgkin's lymphoma)

oprozomib

pexlimogene devarirepvec

rilimogene gamvarirepvec (prostate cancer)

rilimogene glafolivec (prostate cancer)

saridegib

taranedix

vocimagene amiretrorepvec (recurrent high grade glioma)